Are ARBs or ACE inhibitors preferred for nephropathy in diabetes?
No Thumbnail Available
Authors
Meeting name
Sponsors
Date
Journal Title
Format
Article
Abstract
Angiotensin receptor blockers (ARBs) have been shown to reduce the progression of nephropathy in several consistent studies. While ACE inhibitors have not been as well studied for the endpoint of nephropathy, patients with nephropathy exhibit reduced mortality when treated with an ACE inhibitor (strength of recommendation: A, based on randomized controlled trials).
Table of Contents
DOI
PubMed ID
Degree
Thesis Department
Rights
OpenAccess.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.